Iason GmbH has continued its refinancing efforts with local banks based on an IBR
The shareholders of Iason GmbH have completed a restructuring of the company and its refinancing efforts with local banks based on an IBR.
The Iason group produces radiopharmaceuticals and supplies special laboratory products to the target group "nuclear medicine" and "laboratory medicine" providing innovative products with the highest quality standards. The company has customers from all over Europe.
Oaklins' team in Austria assisted Iason with the preparation of the IBR (independent business review) and negotiations with local banks regarding refinancing possibilities.
Talk to the deal team
Related deals
Cerbios-Pharma has been acquired by HAS Healthcare
Cerbios-Pharma S.A. has been acquired by HAS Healthcare Advanced Synthesis S.A., forming a leading global contract development and manufacturing organization (CDMO) group. This transaction results in a seamless integration of complementary capabilities, combining extensive expertise in production, chemical and biological sciences and technical excellence, all designed to meet the evolving demands of the global pharmaceutical sector.
Learn morePharma-Skan & Skan-Medic have been acquired by Brygge Partners
Pharma-Skan, an independent contract manufacturing organization (CMO), and Skan-Medic, a manufacturer of over-the-counter (OTC) products, both operating as a joint entity, have been acquired by Brygge Partners.
Learn moreThe Canton of Solothurn had a valuation report prepared for its hospitals
The Canton of Solothurn is the owner of Solothurner Spitäler AG (soH), with its three hospitals in Solothurn, Olten and Dornach.
Learn more